Existing evidence of physical interactions between β2M with CD1d, CD1b, and FCGRT suggests that these interactions may play an important functional role in the context of APCs, supported by the fact that β2M deficiencies significantly reduce the tumor antigen presentation via MHC-I, resulting in poor ICT outcome (2). This evidence concerns the gene B2M and neoplasm.